Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.

ABSTRACT: Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate retention of leukocytes is a hallmark of chronic inflammation and a potentially promising therapeutic target. Here we discuss the clinical trial results of vedolizumab (anti-α4β7, LDP-02, MLN-02, and MLN0002) and its impact on future management of inflammatory bowel disease.

SUBMITTER: Krupka N 

PROVIDER: S-EPMC4277125 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature